|
| 37652664 | The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer. | Cold Spring Harb Mol Case Stud | 2024 |
| 37714742 | Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. | Eur Urol | 2024 |
| 36382533 | Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer. | Prostate | 2023 |
| 37585665 | Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? | Future Oncol | 2023 |
| 37608258 | Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4Â weeks versus 2Â weeks (SHORTER). | BMC Cancer | 2023 |
| 37424145 | Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy. | Prostate | 2023 |
| 37121850 | Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. | Eur Urol | 2023 |
| 37018920 | Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. | J Clin Oncol | 2023 |
| 37251627 | Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. | EClinicalMedicine | 2023 |
| 37040594 | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37071838 | Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After â¿¥2 Years of Follow-Up. | J Clin Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36697317 | Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. | Clin Genitourin Cancer | 2023 |
| 36787737 | Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. | Cell Rep Med | 2023 |
| 36831409 | Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. | Cancers (Basel) | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36795843 | Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. | J Clin Oncol | 2023 |
| 36756959 | Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. | J Urol | 2023 |
| 36627145 | New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. | J Immunother Cancer | 2023 |
| 36240478 | FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. | J Clin Oncol | 2023 |
| 34518652 | Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. | Prostate Cancer Prostatic Dis | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35643841 | Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. | Eur J Cancer | 2022 |
| 35568679 | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. | Eur J Cancer | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35388003 | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. | Nat Commun | 2022 |
| 35714477 | Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. | ESMO Open | 2022 |
| 35656777 | Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. | Future Oncol | 2022 |
| 35483877 | Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab. | Cold Spring Harb Mol Case Stud | 2022 |
| 35416053 | Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. | Future Oncol | 2022 |
| 35964470 | Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. | Eur J Cancer | 2022 |
| 36226865 | Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? | Future Oncol | 2022 |
| 36387205 | Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment. | Front Oncol | 2022 |
| 35046520 | Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. | Br J Cancer | 2022 |
| 35190653 | Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). | Prostate Cancer Prostatic Dis | 2022 |
| 35042068 | Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. | Eur J Cancer | 2022 |
| 35247908 | Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. | Clin Cancer Res | 2022 |
| 35179323 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. | N Engl J Med | 2022 |
| 35029306 | Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. | Br J Clin Pharmacol | 2022 |
| 34965947 | The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. | Clin Cancer Res | 2022 |
| 35231161 | The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. | Mol Oncol | 2022 |
| 34636627 | Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. | Future Oncol | 2022 |
| 33190043 | Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. | Transl Oncol | 2021 |
| 33494937 | Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. | Eur Urol | 2021 |
| 33794293 | Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. | Ann Oncol | 2021 |
| 33738495 | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. | Jpn J Clin Oncol | 2021 |
| 33822655 | Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. | J Clin Oncol | 2021 |
| 33729863 | Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. | J Clin Oncol | 2021 |
| 33839438 | Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. | Cancer Treat Rev | 2021 |
| 33835866 | Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. | J Urol | 2021 |